Vy1706 Low Dose, Vy1706 Mid Dose, Vy1706 High Dose, Anti-Aav9 Total Antibody Assay
Alzheimer S Disease
Phase I
Not Yet Recruiting
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Aug 04, 2026
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Voyager Therapeutics (VYGR) have in its pipeline
VYGR is currently developing the following drugs: Vy1706 Low Dose, Vy1706 Mid Dose, Vy1706 High Dose, Anti-Aav9 Total Antibody Assay, Vy7523. These drug candidates are in various stages of clinical development as the company works toward FDA approval.